Press Releases

12.21.2016

Circle Pharma, developer of macrocyclic peptide therapeutics, announces Series A financing and appoints Walter H. Moos, Ph.D., to its board

12.21.2016

FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer

12.20.2016

Draper to Build Preclinical Microphysiological Systems with Pfizer to Help Predict Clinical Outcomes

12.19.2016

Pfizer Presents Data from PALOMA-2 Phase 3 Study Demonstrating Clinical Benefit of IBRANCE® (palbociclib) in Asian Women with ER+, HER2- Metastatic Breast Cancer at ESMO Asia Congress

12.19.2016

Pfizer Receives Approval in the European Union for Nimenrix™ (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older

12.16.2016

FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX® (varenicline) Labeling

12.14.2016

Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema)

12.14.2016

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer

12.14.2016

Pfizer Announces FDA Approval of EUCRISA™ (crisaborole)

12.13.2016

Pediatric Open Innovation Challenge Grantees Awarded $50,000 by the Institute for Pediatric Innovation and Pfizer

12.13.2016

Ab Initio Announces Strategic Collaboration with Pfizer to Discover GPCR Activating Antibodies

12.13.2016

Pfizer Declares First-Quarter 2017 Dividend